# Development of an Anthrax Vaccine

> **NIH NIH N01** · EMERGENT PRODUCT DEVELOPMENT GAITHERSBUR · 2021 · $2,562,540

## Abstract

This contract supports the advanced development of an immuno-enhanced version of the licensed anthrax vaccine through cGMP manufacturing and has an option for a Phase 1 clinical trial. The candidate vaccine will be formulated with an immunostimulant to minimize the amount of vaccine and time required to attain protective immunity.

## Key facts

- **NIH application ID:** 10434631
- **Project number:** 272200800051C-P00009-9999-1
- **Recipient organization:** EMERGENT PRODUCT DEVELOPMENT GAITHERSBUR
- **Principal Investigator:** SUKJOON PARK
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $2,562,540
- **Award type:** —
- **Project period:** 2008-09-25 → 2021-07-07

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10434631

## Citation

> US National Institutes of Health, RePORTER application 10434631, Development of an Anthrax Vaccine (272200800051C-P00009-9999-1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10434631. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*